Mr. James H. Quigley - B.S., Accounting, 1974
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of James Quigley, CEO emeritus of Deloitte Touche Tohmatsu, Limited (the Deloitte Global Network), to its Board of Directors. Quigley recently retired as a Senior Partner with Deloitte LLP. He is the co-author of "As One: Individual Action, Collective Power" (2011), a book that addresses the leadership challenge of creating environments that inspire large groups to work together toward a common goal. Quigley is engaged in numerous business organizations and committees and brings a history of involvement in various business and community groups including being the U.S. co-chairman of the TransAtlantic Business Dialogue, a member of the Council on Competitiveness and a former member of the U.S. Securities and Exchange Commission (SEC) Advisory Committee on Improvements to Financial Reporting. "Jim's experience as a leader in a global firm and his expertise in financial reporting make him a fantastic addition to Merrimack as we advance our portfolio of oncology therapeutics and diagnostics and continue to build an innovative, global medicine company," said Gary Crocker, Chairman of the Board of Merrimack. Quigley earned a Bachelor of Science degree and an honorary Doctorate of Business from Utah State University. He was awarded an honorary degree of Doctor of Commercial Science from Bentley College in Waltham, Massachusetts. "I am delighted to join the Merrimack Board and appreciate the privilege of working with Gary and the other Board members. I look forward to supporting and guiding the management team in pursuit of Merrimack's ambitious mission to transform drug development in a way that will offer patients and physicians better treatment options and outcomes," said Quigley. Merrimack also announced today the resignation of Robert Gay, Ph.D. Gay is the former Managing Director and Chief Executive Officer of Huntsman Gay Global Capital, a private equity firm, which he co-founded in 2008 and, prior to that, was a Managing Director of Bain Capital for 16 years. Gay has served as a member of Merrimack's Board since 2007. "Bob's expertise has been a great asset to Merrimack. We are grateful for the guidance and support he has offered during his tenure on our Board," said Robert Mulroy, President and CEO of Merrimack.